ArticleJournal of the Chinese Medical Association : JCMA2025
Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interactive Roles of Metabolic Dysfunction-Associated Steatotic Liver Disease and Nutritional Status in the Prognosis of Patients With Hepatocellular Carcinoma After Surgical Resection.The Kaohsiung journal of medical sciences · 2026Article
- Comparison of patients with HCC with and without MASLD after surgical resection.JHEP reports : innovation in hepatology · 2026Article
- Gallbladder Schwannoma: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular Mechanisms of EDC-Induced Alzheimer's Disease and of Traditional Chinese Medicine Active Substances in Treating AD and Antagonizing EDC-Induced Effects.Neurochemical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlpha-fetoprotein (AFP) has been the primary biomarker for hepatocellular carcinoma (HCC), but a subset of patients with HCC have normal serum levels of AFP (<20 ng/mL). Reliable biomarkers for predicting prognosis in this population remain limited. Protein induced by vitamin K absence or antagonist II (PIVKA-II) has emerged as a promising diagnostic marker for HCC, but its prognostic value for patients with normal AFP has not been well established. Therefore, this study investigated its prognostic significance in such patients.
methodsWe retrospectively analyzed 330 consecutive treatment-naïve patients with HCC who had normal serum levels of AFP and were diagnosed between 2020 and 2023 at Taipei Veterans General Hospital. Patients were stratified into two groups according to serum levels of PIVKA-II (>100 vs ≤100 mAU/mL). Prognostic factors for overall survival (OS) were assessed using multivariate Cox proportional-hazards models.
resultsThere were 169 (51.2%) patients in the study population who had elevated PIVKA-II levels (>100 mAU/mL). These patients demonstrated more aggressive tumor characteristics, including larger tumor size, multinodularity, macrovascular invasion, and extrahepatic metastases compared to those with PIVKA-II ≤100 mAU/mL, despite having comparable liver functional reserves. Patients with high PIVKA-II levels were also less likely to undergo curative treatment (53.3% vs 83.2%, p < 0.001). After a median follow-up of 17 months (interquartile range: 8.0-27.0), 50 patients had died, and the overall 3-year OS rate was 77%. OS was significantly lower in the high-PIVKA-II group than the low-PIVKA-II group (54.9% vs 87.1%, p < 0.001). Multivariate analysis identified elevated PIVKA-II as an independent predictor for poor OS (hazard ratio: 2.422, 95% CI, 1.128-5.198, p = 0.023).
conclusionSerum PIVKA-II is an independent prognostic biomarker for patients with HCC who have normal AFP levels and can be used to stratify patients into distinct risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.